

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))Docket No.  
RLL-299USIn Re Application Of: **BISWAS et al.**

10/533246

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/533,246	10/30/03	TBA	26815	TBA	TBA

Title:

**AMORPHOUS MOXIFLOXACIN HYDROCHLORIDE**

Address to:

**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450****37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
RLL-299US

In Re Application of: **BISWAS et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/533,246	10/30/03	TBA	26815	TBA	TBA

Title:  
**AMORPHOUS MOXIFLOXACIN HYDROCHLORIDE**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912  
as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa
_____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as <u>first class mail in an envelope addressed to</u> "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on
_____ (Date)
_____ Signature of Person Mailing Correspondence
_____ Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

William Hare  
Signature

Dated: 16 February 2006

William D. Hare  
Reg. No. 44,739  
Ranbaxy Inc.  
600 College Road East, Suite 2100  
Princeton, NJ 08540  
Tel.: (609) 720-5378  
Fax: (609) 514-9779

CC:

**INFORMATION DISCLOSURE CITATION**

Docket No.: RL 9US

Serial No.: 10/533,246

Applicants: BISWAS *et al.*

Filed: 4/29/2005

Group:

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,990,517	2/5/1991	Petersen <i>et al.</i>	514	300	
	A2	5,607,942	3/4/1997	Petersen <i>et al.</i>	546	200	
	A3	5,849,752	12/15/1998	Grunenberg <i>et al.</i>	514	300	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO	

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Konne, <i>Chem. Pharm. Bull.</i> , 38:2003 (1990)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.